Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Sep 14, 2018 at 11:05 AM EDT

Principia Biopharma Adds Even More Shares to IPO

Principia Biopharma now intends to price more than 6 million shares for an initial public offering valued up to more…

Chris Lange | Sep 14, 2018 at 10:10 AM EDT

What This FDA Approval Means for STAAR Surgical

STAAR Surgical shares made a handy gain on Friday after the firm announced a key approval by the FDA.

Chris Lange | Sep 14, 2018 at 9:45 AM EDT

Allogene Therapeutics Files for IPO

Clinical-stage immuno-oncology company Allogene Therapeutics has filed with the SEC in regards to its initial public offering.

Chris Lange | Sep 13, 2018 at 11:20 AM EDT

Can Acorda Therapeutics Get Past This FDA Move?

Acorda Therapeutics shares dipped on Thursday after the company announced that the FDA would be delaying its Prescription Drug User…

Chris Lange | Sep 13, 2018 at 10:55 AM EDT

Why Progenics Shares Are Getting Crushed

Progenics Pharmaceuticals shares dropped on Thursday after the company announced late-stage results from its prostate cancer study.

Chris Lange | Sep 13, 2018 at 9:55 AM EDT

Short Sellers Back Off Major Pharma Stocks

The August 31 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Sep 13, 2018 at 8:20 AM EDT

Short Sellers Up the Ante in Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data…

Chris Lange | Sep 12, 2018 at 11:20 AM EDT

The FDA Crackdown on Teen Vaping Just Got Real

The FDA is cracking down on smoking, but not what is traditionally considered smoking. The agency is going after e-cigarette…

Chris Lange | Sep 12, 2018 at 10:30 AM EDT

Is Vital Therapies Done?

Vital Thearpies shares were absolutely crushed on Wednesday after the company announced less-than-favorable results for its liver failure trial.

Chris Lange | Sep 12, 2018 at 9:55 AM EDT

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Gilead shares were up handily on Wednesday after the company announced that it had entered into a strategic collaboration with…

Chris Lange | Sep 12, 2018 at 9:50 AM EDT

Why Foamix Shares Are Booming

Foamix Pharmaceuticals shares were last seen up early on Wednesday after the company announced a solid performance in its late-stage…

Chris Lange | Sep 11, 2018 at 1:45 PM EDT

Why Endocyte’s Secondary Offering Is Actually Pushing the Stock Higher

Endocyte filed with the SEC for a secondary offering. In most cases where a company does this, we see the…

Chris Lange | Sep 11, 2018 at 10:55 AM EDT

Merrill Lynch Sees 4 Top Biotechs With Key Catalysts in 2018

With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the…

Chris Lange | Sep 10, 2018 at 9:40 AM EDT

Why Endocyte Shares Are Booming

Endocyte shares made a solid gain early on Monday after the company announced an update from the FDA.

Chris Lange | Sep 8, 2018 at 7:10 AM EDT

Major Biopharma Catalysts on September’s FDA Calendar

Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food…

1 … 120 121 122 123 124 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Principia Biopharma Adds Even More Shares to IPO

What This FDA Approval Means for STAAR Surgical

Allogene Therapeutics Files for IPO

Can Acorda Therapeutics Get Past This FDA Move?

Why Progenics Shares Are Getting Crushed

Short Sellers Back Off Major Pharma Stocks

Short Sellers Up the Ante in Major Biotechs

The FDA Crackdown on Teen Vaping Just Got Real

Is Vital Therapies Done?

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Why Foamix Shares Are Booming

Why Endocyte’s Secondary Offering Is Actually Pushing the Stock Higher

Merrill Lynch Sees 4 Top Biotechs With Key Catalysts in 2018

Why Endocyte Shares Are Booming

Major Biopharma Catalysts on September’s FDA Calendar

Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

Live: onsemi Q1 Earnings Tonight. Can the Stock Continue Its 90% YTD Rally?

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

KLA Is Gaining Share as AI Chip Complexity Drives Up Yield Costs

Magna Stock Craters 10% as Strong Q1 Fails to Lift Full-Year Outlook

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Health and Healthcare Articles

All Health and Healthcare Articles

Principia Biopharma Adds Even More Shares to IPO

What This FDA Approval Means for STAAR Surgical

Allogene Therapeutics Files for IPO

Can Acorda Therapeutics Get Past This FDA Move?

Why Progenics Shares Are Getting Crushed

Short Sellers Back Off Major Pharma Stocks

Short Sellers Up the Ante in Major Biotechs

The FDA Crackdown on Teen Vaping Just Got Real

Is Vital Therapies Done?

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Why Foamix Shares Are Booming

Why Endocyte’s Secondary Offering Is Actually Pushing the Stock Higher

Merrill Lynch Sees 4 Top Biotechs With Key Catalysts in 2018

Why Endocyte Shares Are Booming

Major Biopharma Catalysts on September’s FDA Calendar

Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

Live: onsemi Q1 Earnings Tonight. Can the Stock Continue Its 90% YTD Rally?

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

KLA Is Gaining Share as AI Chip Complexity Drives Up Yield Costs

Magna Stock Craters 10% as Strong Q1 Fails to Lift Full-Year Outlook

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how